A phase II study of Iressa and vinorelbine/gemcitabine in chemo-naive elderly patients with advanced non-small-cell lung cancer screened for EGFR mutation status.

A phase II study of Iressa and vinorelbine/gemcitabine in chemo-naive elderly patients with advanced non-small-cell lung cancer screened for EGFR mutation status. - IVAN Trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000436

Enrollment

Registered

2006-06-23

Start date

2006-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small-cell lung cancer

Interventions

Patients whose tumor has an EGFR mutation are treated with gefitinib. Patients whose tumor has a wild-type EGFR are treated with vinorelbine or gemcitabine.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Histologically confirmed non-small-cell lung cancer 2.Adequate biopsy sample for EGFR mutation analysis 3.Stage IIIB or IV disease unsuitable for curative radiotherapy 4.Age of 70 or older 5.Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 6.Adequate organ function 7.Written informed consent was obtained

Exclusion criteria

Exclusion criteria: 1.Symptomatic brain metastasis 2.Patients who received previous chemotherapy 3.Overt interstitial pneumonia in chest CT

Design outcomes

Primary

Measure	Time frame
Response rate	—

Countries

Japan

Contacts

Public ContactShiro Fujita

Kyoto University Hospital Department of Respiratory Medicine

sfujita@kuhp.kyoto-u.ac.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026